TY - JOUR T1 - Identification of novel genetic variants in the malaria vaccine candidate PfRh5: structure-guided insights into potential function JF - medRxiv DO - 10.1101/2022.03.17.22271950 SP - 2022.03.17.22271950 AU - Khadidiatou Mangou AU - Adam J. Moore AU - Laty Gaye Thiam AU - Aboubacar Ba AU - Alessandra Orfanó AU - Ife Desamours AU - Duncan Ndungu Ndegwa AU - Justin Goodwin AU - Yicheng Guo AU - Zizhang Sheng AU - Saurabh D. Patel AU - Fatoumata Diallo AU - Seynabou D. Sene AU - Mariama N. Pouye AU - Awa Thioub Faye AU - Vanessa Nunez AU - Cheikh Tidiane Diagne AU - Bacary Djilocalisse Sadio AU - Lawrence Shapiro AU - Ousmane Faye AU - Alassane Mbengue AU - Amy K. Bei Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/03/20/2022.03.17.22271950.abstract N2 - The recent stall in the global reduction of malaria deaths has made the development of a highly effective vaccine essential. A major challenge to developing an efficacious vaccine is the extensive diversity of Plasmodium falciparum antigens. While genetic diversity plays a major role in immune evasion and is a barrier to the development of both natural and vaccine-induced protective immunity, it has been under-prioritized in the evaluation of malaria vaccine candidates. This study uses genomic approaches to evaluate genetic diversity in next generation malaria vaccine candidate PfRh5. We used targeted deep amplicon sequencing to identify non-synonymous Single Nucleotide Polymorphisms (SNPs) in PfRH5 (Reticulocyte-Binding Protein Homologue 5) in 189 P. falciparum positive samples from Southern Senegal and identified 74 novel SNPs. We evaluated the population prevalence of these SNPs as well as the frequency in individual samples and found that only a single SNP, C203Y, was present at every site. Many SNPs were unique to the individual sampled, with over 90% of SNPs being found in just one infected individual. In addition to population prevalence, we assessed individual level SNP frequencies which revealed that some SNPs were dominant (frequency of greater than 25% in a polygenomic sample) whereas most were rare, present at 2% or less of total reads mapped to the reference at the given position. Structural modeling uncovered 3 novel SNPs occurring under epitopes bound by inhibitory monoclonal antibodies, potentially impacting immune evasion, while other SNPs were predicted to impact PfRh5 structure or interactions with the receptor or binding partners. Our data demonstrate that PfRh5 exhibits greater genetic diversity than previously described, with the caveat that most of the uncovered SNPs are at a low overall frequency in the individual and prevalence in the population. The structural studies reveal that novel SNPs could have functional implications on PfRh5 receptor binding, complex formation, or immune evasion, supporting continued efforts to validate PfRh5 as an effective malaria vaccine target and development of a PfRh5 vaccine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by G4 group funding (G45267, Malaria Experimental Genetic Approaches & Vaccines) from the Institut Pasteur de Paris and Agence Universitaire de la Francophonie (AUF) to AKB, Yale School of Public Health Start-up funds to AKB, Wilbur Downs Fellowship to AJM, and a Crick African Network Grant CAN/B00002/1 to AM. AKB is supported by an International Research Scientist Development Award (K01 TW010496) from the Fogarty International Center of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted with ethical approval from the National Ethics Committee of Senegal (CNERS) and the Institutional Review Board of the Yale School of Public Health.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing Reads associated with this study have been deposited in the NCBI SRA with the BioProject Accession: PRJNA811159. All data produced are available online at https://www.ncbi.nlm.nih.gov//bioproject/PRJNA811159 https://www.ncbi.nlm.nih.gov//bioproject/PRJNA811159 ER -